200 related articles for article (PubMed ID: 24024505)
1. Evaluation of the cytotoxic effect of camptothecin solid lipid nanoparticles on MCF7 cells.
Acevedo-Morantes CY; Acevedo-Morantes MT; Suleiman-Rosado D; Ramírez-Vick JE
Drug Deliv; 2013 Nov; 20(8):338-48. PubMed ID: 24024505
[TBL] [Abstract][Full Text] [Related]
2. Development and evaluation of lipid nanoparticles for camptothecin delivery: a comparison of solid lipid nanoparticles, nanostructured lipid carriers, and lipid emulsion.
Huang ZR; Hua SC; Yang YL; Fang JY
Acta Pharmacol Sin; 2008 Sep; 29(9):1094-102. PubMed ID: 18718178
[TBL] [Abstract][Full Text] [Related]
3. Brain targeting effect of camptothecin-loaded solid lipid nanoparticles in rat after intravenous administration.
Martins SM; Sarmento B; Nunes C; Lúcio M; Reis S; Ferreira DC
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):488-502. PubMed ID: 23994244
[TBL] [Abstract][Full Text] [Related]
4. Redox sensitive lipid-camptothecin conjugate encapsulated solid lipid nanoparticles for oral delivery.
Du Y; Ling L; Ismail M; He W; Xia Q; Zhou W; Yao C; Li X
Int J Pharm; 2018 Oct; 549(1-2):352-362. PubMed ID: 30099214
[TBL] [Abstract][Full Text] [Related]
5. Camptothecin in sterically stabilized phospholipid micelles: a novel nanomedicine.
Koo OM; Rubinstein I; Onyuksel H
Nanomedicine; 2005 Mar; 1(1):77-84. PubMed ID: 17292061
[TBL] [Abstract][Full Text] [Related]
6. Camptothecin analogues with enhanced antitumor activity at acidic pH.
Adams DJ; Dewhirst MW; Flowers JL; Gamcsik MP; Colvin OM; Manikumar G; Wani MC; Wall ME
Cancer Chemother Pharmacol; 2000; 46(4):263-71. PubMed ID: 11052623
[TBL] [Abstract][Full Text] [Related]
7. Brain delivery of camptothecin by means of solid lipid nanoparticles: formulation design, in vitro and in vivo studies.
Martins S; Tho I; Reimold I; Fricker G; Souto E; Ferreira D; Brandl M
Int J Pharm; 2012 Dec; 439(1-2):49-62. PubMed ID: 23046667
[TBL] [Abstract][Full Text] [Related]
8. Sensitivity to camptothecin of human breast carcinoma and normal endothelial cells.
Jones CB; Clements MK; Wasi S; Daoud SS
Cancer Chemother Pharmacol; 1997; 40(6):475-83. PubMed ID: 9332461
[TBL] [Abstract][Full Text] [Related]
9. Biologically active camptothecin derivatives for incorporation into liposome bilayers and lipid emulsions.
Lundberg BB
Anticancer Drug Des; 1998 Jul; 13(5):453-61. PubMed ID: 9702210
[TBL] [Abstract][Full Text] [Related]
10. Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethylene glycol) conjugates in sensitive and multidrug-resistant human ovarian carcinoma cells.
Minko T; Paranjpe PV; Qiu B; Lalloo A; Won R; Stein S; Sinko PJ
Cancer Chemother Pharmacol; 2002 Aug; 50(2):143-50. PubMed ID: 12172980
[TBL] [Abstract][Full Text] [Related]
11. Nanocarrier improves the bioavailability, stability and antitumor activity of camptothecin.
Tang XJ; Han M; Yang B; Shen YQ; He ZG; Xu DH; Gao JQ
Int J Pharm; 2014 Dec; 477(1-2):536-45. PubMed ID: 25445532
[TBL] [Abstract][Full Text] [Related]
12. Hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy.
Min KH; Park K; Kim YS; Bae SM; Lee S; Jo HG; Park RW; Kim IS; Jeong SY; Kim K; Kwon IC
J Control Release; 2008 May; 127(3):208-18. PubMed ID: 18336946
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel-induced apoptosis is blocked by camptothecin in human breast and pancreatic cancer cells.
Jeansonne DP; Koh GY; Zhang F; Kirk-Ballard H; Wolff L; Liu D; Eilertsen K; Liu Z
Oncol Rep; 2011 May; 25(5):1473-80. PubMed ID: 21331447
[TBL] [Abstract][Full Text] [Related]
14. Liposomal formulations of poorly soluble camptothecin: drug retention and biodistribution.
Flaten GE; Chang TT; Phillips WT; Brandl M; Bao A; Goins B
J Liposome Res; 2013 Mar; 23(1):70-81. PubMed ID: 23210622
[TBL] [Abstract][Full Text] [Related]
15. Preparation, formula optimization and antitumor actions of mannitol coupling camptothecin nanoparticles.
Wang Z; Li Q; Zhao X; Sun B; Zhu Q; Gao W; Hua C
Int J Pharm; 2014 Apr; 465(1-2):360-7. PubMed ID: 24530520
[TBL] [Abstract][Full Text] [Related]
16. Solid lipid nanoparticles of anticancer drugs against MCF-7 cell line and a murine breast cancer model.
Zhuang YG; Xu B; Huang F; Wu JJ; Chen S
Pharmazie; 2012 Nov; 67(11):925-9. PubMed ID: 23210242
[TBL] [Abstract][Full Text] [Related]
17. Nanosponge-encapsulated camptothecin exerts anti-tumor activity in human prostate cancer cells.
Minelli R; Cavalli R; Ellis L; Pettazzoni P; Trotta F; Ciamporcero E; Barrera G; Fantozzi R; Dianzani C; Pili R
Eur J Pharm Sci; 2012 Nov; 47(4):686-94. PubMed ID: 22917641
[TBL] [Abstract][Full Text] [Related]
18. Chitosan stabilized camptothecin nanoemulsions: Development, evaluation and biodistribution in preclinical breast cancer animal mode.
Natesan S; Sugumaran A; Ponnusamy C; Thiagarajan V; Palanichamy R; Kandasamy R
Int J Biol Macromol; 2017 Nov; 104(Pt B):1846-1852. PubMed ID: 28545970
[TBL] [Abstract][Full Text] [Related]
19. Investigation of parameters influencing incorporation, retention and cellular cytotoxicity in liposomal formulations of poorly soluble camptothecin.
Whitaker RD; Ingebrigtsen SG; Naderkhani E; Skar ML; Flaten GE
J Liposome Res; 2013 Dec; 23(4):298-310. PubMed ID: 23763495
[TBL] [Abstract][Full Text] [Related]
20. Identification of mutations at DNA topoisomerase I responsible for camptothecin resistance.
Wang LF; Ting CY; Lo CK; Su JS; Mickley LA; Fojo AT; Whang-Peng J; Hwang J
Cancer Res; 1997 Apr; 57(8):1516-22. PubMed ID: 9108454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
